Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

IntraPace closes $30mm Series D financing

Executive Summary

IntraPace (implantable devices for obesity) brought in $30mm through an oversubscribed Series D round led by new investor Vulcan Capital. Other first-time backer L Capital Partners was joined by returning shareholders DFJ ePlanet, Oxford Bioscience Partners, Toucan Capital, Guidant, Johnson & Johnson Development Corp., CB Health Ventures, and Halo Fund II (managed by The Angel's Forum). A member of Vulcan Capital and L Capital Partners will take seats on the company's board. IntraPace will use the proceeds for clinical trials of its endoscopic gastric pacemaker.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies